Targeting information-processing deficit in schizophrenia: a novel approach to psychotherapeutic drug discovery

Trends in Pharmacological Sciences

Volumn 27, Issue 7, 2006, Pages 391-398

  Hajós, Mihály ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; BIOLOGICAL MARKER; CLOZAPINE; HALOPERIDOL; HISTAMINE H3 RECEPTOR ANTAGONIST; NEUROLEPTIC AGENT; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; ONDANSETRON; PNU 282987; ROLIPRAM; TROPISETRON; UNCLASSIFIED DRUG;

COGNITIVE DEFECT; CORTICAL SYNCHRONIZATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ELECTROENCEPHALOGRAM; EVENT RELATED POTENTIAL; EVOKED AUDITORY RESPONSE; HUMAN; MISMATCH NEGATIVITY; NERVE CELL NETWORK; NEUROPHYSIOLOGY; NONHUMAN; OSCILLATION; PATHOPHYSIOLOGY; PERCEPTION; PHYLOGENY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SENSORY SYSTEM;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; DRUG DESIGN; ELECTROENCEPHALOGRAPHY; ELECTROPHYSIOLOGY; HUMANS; MENTAL PROCESSES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 33745512492     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2006.05.005     Document Type: Review

References (75)

1. Markand O.N. Pearls, perils, and pitfalls in the use of the electroencephalogram. Semin. Neurol. 23 (2003) 7-46
2. Torrey E.F. Studies of individuals with schizophrenia never treated with antipsychotic medications: a review. Schizophr. Res. 58 (2002) 101-115
3. Weinberger D.R., et al. Prefrontal neurons and the genetics of schizophrenia. Biol. Psychiatry 50 (2001) 825-844
4. Robbins T.W. Synthesizing Schizophrenia: A Bottom-Up, Symptomatic Approach. Schizophr. Bull. 31 (2005) 854-864
5. Mientus S., et al. Cortical hypoactivation during resting EEG in schizophrenics but not in depressives and schizotypal subjects as revealed by low resolution electromagnetic tomography (LORETA). Psychiatry Res. 116 (2002) 95-111
6. Koles Z.J., et al. A source-imaging (low-resolution electromagnetic tomography) study of the EEGs from unmedicated men with schizophrenia. Psychiatry Res. 130 (2004) 171-190
7. Pascual-Marqui R.D., et al. Low resolution brain electromagnetic tomography (LORETA) functional imaging in acute, neuroleptic-naive, first-episode, productive schizophrenia. Psychiatry Res. 90 (1999) 169-179
8. Lehmann D., et al. EEG microstate duration and syntax in acute, medication-naive, first-episode schizophrenia: a multi-center study. Psychiatry Res. 138 (2005) 141-156
9. Buzsaki G., and Draguhn A. Neuronal oscillations in cortical networks. Science 304 (2004) 1926-1929
10. Lee K.H., et al. Synchronous gamma activity: a review and contribution to an integrative neuroscience model of schizophrenia. Brain Res. Brain Res. Rev. 41 (2003) 57-78
11. van der Stelt O., et al. Macroscopic fast neuronal oscillations and synchrony in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 17567-17568
12. Kwon J.S., et al. Gamma frequency-range abnormalities to auditory stimulation in schizophrenia. Arch. Gen. Psychiatry 56 (1999) 1001-1005
13. Hong L.E., et al. Evoked gamma band synchronization and the liability for schizophrenia. Schizophr. Res. 70 (2004) 293-302
14. Engel A.K., et al. Dynamic predictions: oscillations and synchrony in top-down processing. Nat. Rev. Neurosci. 2 (2001) 704-716
15. Gruber T., et al. Modulation of induced gamma band responses in a perceptual learning task in the human EEG. J. Cogn. Neurosci. 14 (2002) 732-744
16. Fell J., et al. Is synchronized neuronal gamma activity relevant for selective attention?. Brain Res. Brain Res. Rev. 42 (2003) 265-272
17. Gallinat J., et al. Reduced oscillatory gamma-band responses in unmedicated schizophrenic patients indicate impaired frontal network processing. Clin. Neurophysiol. 115 (2004) 1863-1874
18. Spencer K.M., et al. Neural synchrony indexes disordered perception and cognition in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 17288-17293
19. Freund T.F. Interneuron Diversity series: Rhythm and mood in perisomatic inhibition. Trends Neurosci. 26 (2003) 489-495
20. Lewis D.A., et al. Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci. 6 (2005) 312-324
21. Freedman R., et al. The genetics of sensory gating deficits in schizophrenia. Curr. Psychiatry Rep. 5 (2003) 155-161
22. Ji D., and Dani J.A. Inhibition and disinhibition of pyramidal neurons by activation of nicotinic receptors on hippocampal interneurons. J. Neurophysiol. 83 (2000) 2682-2690
23. Hajós M., et al. The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. J. Pharmacol. Exp. Ther. 312 (2005) 1213-1222
24. Song C., et al. Role of alpha7-nicotinic acetylcholine receptors in tetanic stimulation-induced gamma oscillations in rat hippocampal slices. Neuropharmacology 48 (2005) 869-880
25. Hoffmann W.E., et al. Auditory gating in rat entorhinal cortex, medial septum and hippocampus: modeling dysfunctional information processing associated with schizophrenia. Soc. Neurosci. Abstr. (2005) 102310
26. Siok C.J., et al. The effect of the alpha-7 acetylcholine receptor agonist PNU-282987 on hippocampal theta elicited by brainstem stimulation. Eur. J. Neurosci. 23 (2006) 570-574
27. Kitagawa H., et al. Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology 28 (2003) 542-551
28. Van Kampen M., et al. AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors. Psychopharmacology (Berl.) 172 (2004) 375-383
29. Buccafusco J.J., et al. Long-lasting cognitive improvement with nicotinic receptor agonists: mechanisms of pharmacokinetic-pharmacodynamic discordance. Trends Pharmacol. Sci. 26 (2005) 352-360
30. Mansvelder H.D., et al. Nicotinic modulation of neuronal networks: from receptors to cognition. Psychopharmacology (Berl.) 184 (2006) 292-305
31. Spedding M., et al. A pathophysiological paradigm for the therapy of psychiatric disease. Nat. Rev. Drug Discov. 4 (2005) 467-476
32. Lipska B.K., and Weinberger D.R. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 23 (2000) 223-239
33. Whittington M.A., et al. Neuronal fast oscillations as a target site for psychoactive drugs. Pharmacol. Ther. 86 (2000) 171-190
34. A receptors: An experimental and computational approach. Neuroscience 126 (2004) 599-610
35. Schnitzler A., and Gross J. Normal and pathological oscillatory communication in the brain. Nat. Rev. Neurosci. 6 (2005) 285-296
36. Adler L.E., et al. Schizophrenia, sensory gating, and nicotinic receptors. Schizophr. Bull. 24 (1998) 189-202
37. Braff D.L., and Light G.A. Preattentional and attentional cognitive deficits as targets for treating schizophrenia. Psychopharmacology (Berl.) 174 (2004) 75-85
38. Bramon E., et al. Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophr. Res. 70 (2004) 315-329
39. Leitman D.I., et al. Sensory contributions to impaired prosodic processing in schizophrenia. Biol. Psychiatry 58 (2005) 56-61
40. Umbricht D.S., et al. Electrophysiological indices of automatic and controlled auditory information processing in first-episode, recent-onset and chronic schizophrenia. Biol. Psychiatry 59 (2006) 762-772
41. Jessen F., et al. Sensory gating deficit expressed by a disturbed suppression of the P50 event-related potential in patients with Alzheimer's disease. Am. J. Psychiatry 158 (2001) 1319-1321
42. Karl A., et al. A Meta-analytic review of event-related potential studies in post-traumatic stress disorder. Biol. Psychol. 71 (2006) 123-147
43. Light G.A., and Braff D.L. Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Arch. Gen. Psychiatry 62 (2005) 127-136
44. Pekkonen E., et al. Impaired temporal lobe processing of preattentive auditory discrimination in schizophrenia. Schizophr. Bull. 28 (2002) 467-474
45. Thoma R.J., et al. Lateralization of auditory sensory gating and neuropsychological dysfunction in schizophrenia. Am. J. Psychiatry 160 (2003) 1595-1605
46. Boutros N.N., et al. Morphological and latency abnormalities of the mid-latency auditory evoked responses in schizophrenia: a preliminary report. Schizophr. Res. 70 (2004) 303-313
47. Jeon Y.W., and Polich J. Meta-analysis of P300 and schizophrenia: patients, paradigms, and practical implications. Psychophysiology 40 (2003) 684-701
48. Johannesen J.K., et al. Contributions of subtype and spectral frequency analyses to the study of P50 ERP amplitude and suppression in schizophrenia. Schizophr. Res. 78 (2005) 269-284
49. Gilmore C.S., et al. Stimulus sequence affects schizophrenia-normal differences in event processing during an auditory oddball task. Brain Res. Cogn. Brain Res. 24 (2005) 215-227
50. Stevens K.E., et al. Selective alpha 7 nicotinic receptor stimulation normalizes chronic cocaine-induced loss of hippocampal sensory inhibition in C3H mice. Biol. Psychiatry 46 (1999) 1443-1450
51. Adler L.E., et al. Neurophysiological studies of sensory gating in rats: Effects of amphetamine, phencyclidine, and haloperidol. Biol. Psychiatry 21 (1986) 787-798
52. Krause M., et al. Auditory sensory gating in hippocampus and reticular thalamic neurons in anesthetized rats. Biol. Psychiatry 53 (2003) 244-253
53. Ellenbroek B.A. Pre-attentive processing and schizophrenia: animal studies. Psychopharmacology (Berl.) 174 (2004) 65-74
54. Cromwell H.C., et al. Auditory inhibitory gating in the amygdala: single-unit analysis in the behaving rat. Brain Res. 1043 (2005) 12-23
55. Swerdlow N.R., et al. Convergence and Divergence in the Neurochemical Regulation of Prepulse Inhibition of Startle and N40 Suppression in Rats. Neuropsychopharmacology 31 (2005) 506-515
56. Adler L.E., et al. Reversal of diminished inhibitory sensory gating in cocaine addicts by a nicotinic cholinergic mechanism. Neuropsychopharmacology 24 (2001) 671-679
57. Light G.A., et al. Amphetamine disrupts P50 suppression in normal subjects. Biol. Psychiatry 46 (1999) 990-996
58. Hurst R.S., et al. A novel positive allosteric modulator of the α7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J. Neurosci. 25 (2005) 4396-4405
59. Maxwell C.R., et al. Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications. Neuroscience 129 (2004) 101-107
60. Stevens K.E., et al. Selective alpha7-nicotinic agonists normalize inhibition of auditory response in DBA mice. Psychopharmacology (Berl.) 136 (1998) 320-327
61. O'Neill H.C., et al. DMXB, an alpha7 nicotinic agonist, normalizes auditory gating in isolation-reared rats. Psychopharmacology (Berl.) 169 (2003) 332-339
62. Ellenbroek B.A., et al. The effects of early maternal deprivation on auditory information processing in adult Wistar rats. Biol. Psychiatry 55 (2004) 701-707
63. Fox G.B., et al. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. J. Pharmacol. Exp. Ther. 313 (2005) 176-190
64. de Leon J., and Diaz F.J. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr. Res. 76 (2005) 135-157
65. Harkrider A.W., and Hedrick M.S. Acute effect of nicotine on auditory gating in smokers and non-smokers. Hear. Res. 202 (2005) 114-128
66. Adler L.E., et al. Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. Am. J. Psychiatry 161 (2004) 1822-1828
67. Becker J., et al. Clozapine, but not typical antipsychotics, correct P50 suppression deficit in patients with schizophrenia. Clin. Neurophysiol. 115 (2004) 396-401
68. Chung C., and Remington G. Predictors and markers of clozapine response. Psychopharmacology (Berl.) 179 (2005) 317-335
69. Koike K., et al. Tropisetron improves deficits in auditory P50 suppression in schizophrenia. Schizophr. Res. 76 (2005) 67-72
70. Adler L.E., et al. Improved p50 auditory gating with ondansetron in medicated schizophrenia patients. Am. J. Psychiatry 162 (2005) 386-388
71. Lieberman J.A., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 (2005) 1209-1223
72. Pascual-Marqui R.D., et al. Low resolution electromagnetic tomography: a new method for localizing electrical activity in the brain. Int. J. Psychophysiol. 18 (1994) 49-65
73. Boutros N.N., et al. Sensory gating in the human hippocampal and rhinal regions. Clin. Neurophysiol. 116 (2005) 1967-1974
74. Grunwald T., et al. Neuronal substrates of sensory gating within the human brain. Biol. Psychiatry 53 (2003) 511-519
75. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1986), Academic Press